Europe Cervical Cancer Diagnostic Market Size, Share & Industry Trends Analysis Report By Type (Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC), By Age Group (20 to 40 years, and Above 40 years), By Country and Growth Forecast, 2023 - 2029

The Europe Cervical Cancer Diagnostic Market should witness market growth of 4.0% CAGR during the forecast period (2023-2029).

The market has an opportunity owing to the rise in cervical cancer diagnostic tests in healthcare institutions. Additionally, the increased use of cutting-edge technology in introducing new products by numerous major companies is anticipated to benefit the development of the market. New diagnostic methods are being used to identify precancerous lesions, which are thought to represent the next generation of cervical cancer screening. These systems combine deep learning-based artificial intelligence (AI) with cutting-edge volumetric imaging technology.

Due to an increasing need for cervical cancer diagnostics among middle-aged patients, increased R&D activities, and improved test efficiency, the market is anticipated to grow at a high rate in emerging nations. Hospitals and other healthcare facilities are using cutting-edge equipment to detect cervical cancer. Additionally, the affordability of cervical cancer screening tests facilitates the development of the market.

Cervical cancer is becoming more common in this region; predictions indicate that in 2020, cervical cancer will account for 2.5% of all new cancer diagnoses in women in the EU-27 countries (excluding non-melanoma skin cancers) and 2.4% of all cancer-related deaths in women. Cervical cancer is amongst the most prevalent cancer and the most common cause of cancer mortality in women. Cervical cancer incidence and mortality rates were predicted to differ across the EU-27 by five and eight times, respectively, in 2020. This wide range is caused by the fact that varied HPV prevalence, vaccination, and cervical cancer screening programs exist in different EU countries. As a result, the region offers the market promising growth opportunities due to the rising incidences of cervical cancer and the efforts to enhance women's health.

The Germany market dominated the Europe Cervical Cancer Diagnostic Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $694.7 Million by 2029. The UK market is exhibiting a CAGR of 3.1% during (2023-2029). Additionally, The France market would display a CAGR of 4.8% during (2023-2029).

Based on Type, the market is segmented into Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC, and Others. Based on Age Group, the market is segmented into 20 to 40 years, and Above 40 years. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.

Scope of the Study

By Type

• Pap Smear Tests
• Colposcopy Tests
• HPV Test
• Biopsy & ECC
• Others

By Age Group

• 20 to 40 years
• Above 40 years

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Abbott Laboratories
• Becton, Dickinson and Company
• Carl Zeiss AG
• CooperSurgical, Inc. (The Cooper Companies, Inc.)
• DYSIS Medical, Inc.
• F.Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Qiagen N.V.
• Siemens Healthineers AG (Siemens AG)
• Thermo Fisher Scientific, Inc.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free